New hope for advanced breast cancer? Triple-Drug combo tested after key therapy fails

NCT ID NCT07333937

Not yet recruiting Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrink tumors and control the disease longer. Researchers hope to find a new treatment path for patients who have run out of effective options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neratinib combined with fulvestrant and eribulin
What this could lead to: If this works, it could offer a new treatment option for people with a specific type of advanced breast cancer that has stopped responding to a current therapy.
What could go wrong: This is a small, early-phase study (35 people) with no control group, so results may not apply broadly. The drug combination may cause side effects and might not shrink tumors or extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.